A Phase 1 interventional study of LAE118 and Fulvestrant in Patients With Advanced Solid Tumors, sponsored by Laekna Limited. Not yet recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Laekna Limited · Phase 1, Interventional, and Other
Study Title:
A Phase I, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of LAE118 as Monotherapy and in Combination With Other Antitumor Agents in Patients With Advanced Solid Tumors
Study Design Overview:
This is an open-label, multicenter Phase I clinical trial comprising three cohorts: Cohort A (LAE118 monotherapy), Cohort B (LAE118 plus fulvestrant), and Cohort C (LAE118 plus fulvestrant and palbociclib). Each cohort consists of two stages. Stage I evaluates safety and determines the maximum tolerated dose (MTD) and recommended dose (RD) of LAE118; Stage II assesses the preliminary efficacy of LAE118 at the RD.
Histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor, meeting the specific criteria for each cohort:
Cohort A (Stage I, Dose Escalation): Histologically or cytologically confirmed locally advanced (unresectable) or metastatic solid tumor. Lymphoma is excluded.
Cohort A (Stage II): Histologically or cytologically confirmed locally advanced (unresectable) or metastatic head and neck squamous cell carcinoma (HNSCC) or gynecologic cancers (ovarian, cervical, or endometrial cancer).
Cohort A (Stage I, Backfill Enrollment) and Cohorts B/C: Histologically or cytologically confirmed locally advanced (unresectable) or metastatic HR+/HER2- breast cancer, based on the most recent tumor specimen.
HR+/HER2- breast cancer is defined as HER2-negative and ER-positive, regardless of PR expression status.
Estrogen receptor (ER) positive: Defined as ≥1% of tumor cells demonstrating ER positivity by immunohistochemistry (IHC).
Progesterone receptor (PR) positive: Defined as ≥1% of tumor cells demonstrating PR positivity by IHC.
HER2-negative: Defined as IHC intensity of 0 or 1+, or IHC intensity of 2+ without evidence of amplification by in situ hybridization (ISH), or absence of IHC testing and no evidence of amplification by ISH (based on the 2023 updated ASCO-CAP guidelines).
Prior antitumor therapy:
Cohort A: Disease progression after adequate standard therapy, or no effective standard therapy available.
Cohorts B/C:
Receipt of no more than 3 lines of systemic antitumor therapy in the advanced setting (including at least 1 line of endocrine therapy, no more than 1 line of CDK4/6 inhibitor therapy, and no more than 1 line of chemotherapy).
If disease recurrence occurs during adjuvant endocrine therapy or within 12 months of completion of adjuvant endocrine therapy, such adjuvant therapy will be counted as one line of prior therapy.
Prior fulvestrant therapy is permitted; however, the proportion of participants with prior fulvestrant exposure must not exceed 50% of the total enrolled participants in Cohort B and Cohort C, respectively.
Female participants with HR+/HER2- advanced breast cancer who are postmenopausal, premenopausal, or perimenopausal are eligible for enrollment. In Cohorts B/C, male participants and female participants with HR+/HER2- advanced breast cancer who are premenopausal or perimenopausal must receive continuous ovarian function suppression throughout the study period (initiation of luteinizing hormone-releasing hormone agonist [LHRHa] no later than Day 1 of Cycle 1).
Menopause is defined as follows [34]:
Prior bilateral oophorectomy. Age ≥60 years. Age \<60 years with amenorrhea for ≥12 months in the absence of prior chemotherapy, tamoxifen, toremifene, or ovarian suppression, and with estradiol and follicle-stimulating hormone (FSH) levels in the postmenopausal range.
Age \<60 years with chemotherapy-induced amenorrhea for ≥12 months and FSH and estradiol levels consistently in the postmenopausal range upon serial assessment.
Age \<60 years currently receiving tamoxifen with FSH and estradiol levels in the postmenopausal range.
Female participants of childbearing potential must agree to use highly effective contraception from the time of enrollment until at least 1 year after the last dose of study treatment. Acceptable methods include:
Complete abstinence (if this is their preferred and usual lifestyle). Intrauterine device (IUD) or hormonal intrauterine system. Contraceptive implant. Oral contraceptives (combined with barrier contraception). Partner has undergone vasectomy with confirmed azoospermia. Male participants with female partners of childbearing potential must agree to use effective contraception (e.g., condom use) from the time of enrollment until at least 1 year after the last dose of study treatment.
Adequate organ function, defined as follows:
Hematologic: The following criteria must be met without the use of erythropoietin, growth factors, or packed red blood cell transfusion within 14 days prior to screening laboratory assessments:
Absolute neutrophil count (ANC) ≥1.5 × 10⁹/L. Platelet count ≥100 × 10⁹/L. Hemoglobin ≥10.0 g/dL.
Hepatic:
Total bilirubin ≤1.5 × upper limit of normal (ULN). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN (or ≤3 × ULN for participants with liver metastases).
Serum albumin ≥30 g/L.
Renal:
Creatinine clearance ≥60 mL/min (calculated using the Cockcroft-Gault formula).
Coagulation:
International normalized ratio (INR) ≤1.5 × ULN. Activated partial thromboplastin time (aPTT) ≤1.5 × ULN. For participants requiring anticoagulation with warfarin, INR must be stably maintained within the range of 2 to 3. For participants with mechanical heart valves requiring anticoagulation, INR may be maintained within the range of 2.5 to 3.5.
Adrenal function tests during screening show no clinically significant abnormalities.
Exclusion Criteria:
Known active, uncontrolled, or symptomatic central nervous system (CNS) metastases or leptomeningeal carcinomatosis. Participants with previously treated CNS metastases may be enrolled if all of the following criteria are met:
At least one measurable non-CNS lesion per RECIST version 1.1 criteria. No history of intracranial or spinal cord hemorrhage. Radiographic stability: No evidence of progression on imaging following completion of CNS-directed therapy. The interval between post-treatment imaging and screening imaging must be at least 4 weeks, with no evidence of progression.
Clinical stability: No requirement for corticosteroids, diuretics, mannitol, or other agents to reduce intracranial pressure, and no requirement for antiepileptic drugs for at least 14 days prior to the planned start date of study treatment.
Meeting any of the following criteria within 26 weeks prior to the planned start date of study treatment:
History of angina pectoris, coronary artery bypass grafting, symptomatic pericarditis, or myocardial infarction within 12 months prior to initiation of study treatment.
Documented history of congestive heart failure (New York Heart Association [NYHA] Class III-IV).
Documented cardiomyopathy. Left ventricular ejection fraction (LVEF) \<50% (if applicable). History of clinically significant arrhythmias (including but not limited to ventricular tachycardia, complete left bundle branch block, high-grade atrioventricular block, supraventricular tachycardia, or atrial fibrillation).
Active HBV infection (defined as HBsAg positive with HBV DNA ≥200 IU/mL or ≥1000 copies/mL), active HCV infection (defined as anti-HCV antibody positive with detectable HCV RNA), or HIV infection (defined as anti-HIV antibody positive).
Note: As outlined in the U.S. FDA guidance "Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections," participants with well-controlled HIV, HBV, or HCV are eligible. Participants receiving effective antiviral therapy with controlled viral loads should continue the same regimen throughout the study treatment period.
Drug: LAE118
Drug: LAE118 · Drug: Fulvestrant
Drug: LAE118 · Drug: Fulvestrant · Drug: Palbociclib
LAЕ118 is a novel, allosteric and highly potent selective inhibitor of PIK3CA. Its activity against PIK3CA mutant cells is superior to that of other broad-spectrum selective inhibitors.
Fulvestrant is approved for the treatment of post-menopausal metastatic breast cancer following disease progression on therapy with an anti-estrogen therapy.
Palbociclib is a CDK4/6 inhibitor. Multiple clinical studies have shown that palbociclib combined with endocrine therapy has demonstrated significant clinical benefits in study participants with HR+/HER2- advanced breast cancer.
Number of participants with adverse events (AEs)
Frequency and severity of AEs, including treatment-related AEs, serious AEs (SAEs), and AEs leading to treatment discontinuation, as assessed by CTCAE v5.0.
Time frame: From ICF signing to 30 days after last dose, up to ~24 months
Number of participants with dose-limiting toxicities (DLTs)
Per protocol definition. DLT observation period: C0D1-C1D28 for Cohort A; C1D1-C1D28 for Cohorts B and C.
Time frame: 35 days (Cohort A) / 28 days (Cohorts B and C)
Change from baseline in QTcF interval as assessed by 12-lead ECG
Triplicate recordings within 10 min, ≥1 min apart. Fridericia's correction。 Unit: msec
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in PR interval as assessed by 12-lead ECG
Unit: bpm
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in QRS duration as assessed by 12-lead ECG
Unit: msec
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in heart rate as assessed by 12-lead ECG
Unit: bpm
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in systolic and diastolic blood pressure
Unit: mmHg
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in pulse rate
Unit: bpm
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in respiratory rate
Unit: breaths/min
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in body temperature
Unit: °C
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in physical examination findings
Full-body exam at screening and EOT; targeted exam (head/neck, cardiovascular, respiratory, abdominal, musculoskeletal, neurological, skin) at other visits. Presence of clinically significant abnormalities.
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in hematology parameters
WBC with differential (10⁹/L), RBC (10¹²/L), hemoglobin (g/L), hematocrit (%), platelet count (10⁹/L).
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in serum chemistry - enzymes
ALT, AST, ALP, GGT, LDH, CK, CK-MB, amylase, lipase. Unit: U/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in serum chemistry - bilirubin, creatinine, and bile acids
Total bilirubin, direct bilirubin, creatinine, bile acids. Unit: μmol/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in serum chemistry - electrolytes and metabolites
Sodium, potassium, calcium, magnesium, phosphorus, BUN/urea, total cholesterol, HDL-C, LDL-C, triglycerides. Unit: mmol/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in serum albumin and total protein
Unit: g/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in prothrombin time (PT) and activated partial thromboplastin time (aPTT)
Unit: seconds
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in international normalized ratio (INR)
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in fibrinogen
Unit: g/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in thyroid-stimulating hormone (TSH)
mIU/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in free triiodothyronine (FT3) and free thyroxine (FT4)
Unit: pmol/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in adrenal function parameters
Cortisol, ACTH, aldosterone, renin, and aldosterone/renin ratio.
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in troponin I/T
Unit: ng/mL
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in brain natriuretic peptide (BNP)
Unit: pg/mL
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in urinalysis parameters
Urine protein, glucose, ketones, occult blood, and specific gravity.
Time frame: Baseline to EOT, up to ~24 months
Objective response rate (ORR)
Proportion of participants with CR or PR per RECIST v1.1 by investigator assessment.
Time frame: Every 8 weeks from C1D1 to progression/EOT, up to ~24 months
Clinical benefit rate (CBR)
Proportion of participants with CR, PR, or SD ≥24 weeks per RECIST v1.1.
Time frame: Every 8 weeks from C1D1, up to ~24 months
Duration of response (DOR)
Time from first CR/PR to disease progression or death per RECIST v1.1.
Time frame: From first response to progression/death, up to ~24 months
Progression-free survival (PFS)
Time from first dose to disease progression per RECIST v1.1
Time frame: C1D1 to progression/death, up to ~24 months
Peak plasma concentration (Cmax) of LAE118
Peak plasma concentration (Cmax) of LAE118 following single dose (Cycle 0 Day 1 for Cohort A; Cycle 1 Day 1 for Cohorts B and C) and multiple dose (Cycle 1 Day 15). Unit: ng/mL
Time frame: Day 1 and Day 15: pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose.
Time to peak plasma concentration (Tmax) of LAE118
Time to peak plasma concentration (Tmax) of LAE118 following single dose on Day 1 and multiple doses on Day 15. Unit: hours
Time frame: Day 1 and Day 15: pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose.
Area under the plasma concentration-time curve (AUC0-t, AUC0-∞, AUC0-24, AUCtau) of LAE118
Area under the plasma concentration-time curve (AUC0-t, AUC0-∞, AUC0-24, and AUCtau) of LAE118. AUC0-t and AUC0-∞ following both single and multiple doses; AUC0-24 following single dose only (Day 1); AUCtau following multiple doses only (Day 15). Unit: ng·h/mL
Time frame: Day 1 (single-dose period) and Day 15 (multiple-dose period): pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose.
Terminal half-life (t1/2) of LAE118
Following single and multiple dose. Unit: hours
Time frame: Day 1 (single-dose period) and Day 15 (multiple-dose period): pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose.
Apparent volume of distribution (Vz/F) of LAE118
Following single and multiple dose. Unit: L
Time frame: Day 1 (single-dose period) and Day 15 (multiple-dose period): pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose.
Apparent clearance (CL/F) of LAE118
Following single and multiple dose. Unit: L/h
Time frame: Day 1 (single-dose period) and Day 15 (multiple-dose period): pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose.
Trough plasma concentration (Ctrough) of LAE118
Trough plasma concentration (Ctrough) of LAE118 following multiple doses on Cycle 1 Day 15. Unit: ng/mL
Time frame: Pre-dose on Day 15 of Cycle 1 (each cycle is 28 days).
Accumulation ratio (Racc) of LAE118
Accumulation ratio (Racc) of LAE118 following multiple doses (Cycle 1 Day 15 versus single-dose baseline). Unit: ratio
Time frame: Single-dose baseline (Cycle 0 Day 1 for Cohort A; Cycle 1 Day 1 for Cohorts B and C) and multiple-dose steady-state (Cycle 1 Day 15 for all cohorts). Each cycle is 28 days.
Cmax of fulvestrant and palbociclib
Maximum plasma concentration (Cmax) of fulvestrant and palbociclib when co-administered with LAE118 on Cycle 1 Day 1 (single dose) and Cycle 1 Day 15 (multiple doses). Unit: ng/mL
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15: pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose. Each cycle is 28 days.
Tmax of fulvestrant and palbociclib
Time to maximum plasma concentration (Tmax) of fulvestrant and palbociclib when co-administered with LAE118 on Cycle 1 Day 1 (single dose) and Cycle 1 Day 15 (multiple doses). Unit: hours
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15: pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose. Each cycle is 28 days.
AUC0-t of fulvestrant and palbociclib
Area under the plasma concentration-time curve from time 0 to the last quantifiable time point (AUC0-t) of fulvestrant and palbociclib when co-administered with LAE118 on Cycle 1 Day 1 (single dose) and Cycle 1 Day 15 (multiple doses). Unit: ng·h/mL
Time frame: Cycle 1 Day 1 and Cycle 1 Day 15: pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours post-dose. Each cycle is 28 days.
Change from baseline in fasting blood glucose
Unit: mmol/L
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in glycated hemoglobin (HbA1c) and glycated albumin
Unit: %
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in serum C-peptide
Unit: ng/mL
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in serum insulin
Unit: μIU/mL
Time frame: Baseline to EOT, up to ~24 months
Change from baseline in QTcF interval and its relationship with plasma LAE118 concentration
Unit: msec
Time frame: Baseline to EOT, up to ~24 months
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laekna Limited